A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-Disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Aldesleukin (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 09 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2017.
- 09 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated